15 Best Growth Stocks to Buy for the Next 5 Years
Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks.
Aytu Biopharma Inc (AYTU)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,086,812 | $1,304,174 | 0.05% | |
| 2. | Stonepine Capital Timothy P. Lynch | 463,721 | $795,000 | +14% | 0.77% |
| 3. | Renaissance Technologies Jim Simons | 76,823 | $92,188 | +2% | 0% |
| 4. | Armistice Capital Steven Boyd | 57,597 | $69,116 | -62% | 0% |
| 5. | Citadel Investment Group Ken Griffin | 30,493 | $36,592 | +176% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.50 | 16,666 | $24,999.00 | 29,462 | 2025-06-09 | Filing | |
| $1.50 | 66,666 | $99,999.00 | 153,257 | 2025-06-09 | Filing | |
| $1.30 | 15,000 | $19,500.00 | 86,591 | 2025-02-28 | Filing | |
| $1.87 | 12,000 | $22,428.00 | 21,935 | 2023-06-16 | Filing | |
| $1.86 | 14,000 | $26,079.20 | 71,591 | 2023-06-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 0 | $0.00 | 0 | 2020-04-27 | Filing | |
| $1.82 | 5,108,921 | $9,298,236.22 | 0 | 2020-04-27 | Filing | |
| $1.55 | 92,777 | $144,091.96 | 9,713,068 | 2020-04-15 | Filing | |
| $0.00 | 0 | $0.00 | 1 | 2020-03-10 | Filing | |
| $0.99 | 2,456,822 | $2,432,253.78 | 1 | 2020-03-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 53,944 | $64,750 | 0% | |
| 2. | 27,888 | $33,466 | 0% | |
| 3. | 22,793 | $27,352 | 0% | |
| 4. | 17,437 | $20,924 | 0% | |
| 5. | 14,865 | $17,838 | 0% |
News See All
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call Transcript
Operator: Greetings. And welcome to the Aytu BioPharma Fiscal 2025 Q3 Earnings Call. At this time, all participants are in a listen-only.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Aytu BioPharma Fiscal 2025 Q2 Earnings Call. At this time, all participants have been placed on a listen-only.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript
Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2024 Earnings Call Transcript
Operator: Greetings, welcome to the Aytu BioPharma's Fiscal 2024 Q4 Earnings Call. At this time, all participants have been placed on a listen-only mode.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone and welcome to the Aytu BioPharma Fiscal 2024 Third Quarter Earnings Call. At this time, all participants have been placed on a listen-only mode.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript
Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.25. Aytu BioPharma, Inc.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript
Robert Blum: Good afternoon, everyone, and thank you for joining us for Aytu BioPharma's Fiscal 2024 First Quarter Financial Results Conference Call for the period ended September 30, 2023.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q4 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q3 Results Conference Call. At this time, all participants are in a listen-only mode.
Billionaire Hedge Funds
